Skip to main content

Immunotherapy News

Obesity-cancer connection discovery suggests strategies for improving immunotherapy Obesity-cancer connection discovery suggests strategies for improving immunotherapy
The study reported in the journal Nature provides a mechanistic explanation for the obesity paradox that obesity can contribute to cancer progression but also improve response to immunotherapy.
Thursday, June 13th, 2024
Tumor antigens key to improving cancer immunotherapy: study Tumor antigens key to improving cancer immunotherapy study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

Friday, November 17th, 2023
Charles Manning Project seeks new way to assess immunotherapy effectiveness
GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.
Thursday, November 7th, 2019
prostate cancer cells New prostate cancer treatment concept
Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.
Friday, August 30th, 2019
brain scan Encephalitis identified as rare toxicity of immunotherapy treatment
Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Monday, July 22nd, 2019
Breast cancer-killing RIG Breast cancer-killing RIG
A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.
Friday, December 14th, 2018
Lung cancer Combination therapy improves small-cell lung cancer survival
Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.
Friday, October 26th, 2018
MVTCP logo Research conducted by medical students recognized at events
Vanderbilt-Ingram Cancer Center, Meharry Medical College and Tennessee State University Cancer Partnership recently hosted the 2018 annual retreat and poster contest, “Health Disparities in Cancer Immunology & Immune Therapy.”
Monday, March 12th, 2018
Ingrid Mayer Study to test combination therapy for breast cancer
Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Friday, October 27th, 2017
Blind Balko V Foundation grants bolster cancer initiatives
Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC. Raymond Blind, Ph.D.
Thursday, November 17th, 2016
Study details rare heart risk of certain cancer therapies Study details rare heart risk of certain cancer therapies
Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […]
Monday, November 7th, 2016
stem cell transplant VICC treats first patient in Tennessee with novel cellular immunotherapy
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]
Monday, February 29th, 2016